Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

Share Price is delayed by 15 minutes
Get Live Data
7.40    0.00 (0.00%)
Bid:
7.30
Ask:
7.50
Spread: 0.20 (2.74%)
Market Cap: £3.24m
FDBK Live PriceLast checked at - London Stock Exchange

Intraday Feedback Share Chart

Bleepa appointed to major NHSx framework

30 Jul 2020 15:48

RNS Number : 6621U
Feedback PLC
30 July 2020
 

Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement, this information is now considered to be in the public domain.

 

Feedback plc

 

Bleepa® to lead clinical communications revolution through appointment to major NHSx framework

 

NHSx Clinical Communication Tool Framework endorses Bleepa and provides route to payment

The Directors believe that as the only CE marked product for digital patient imaging on the framework Bleepa is the only provider that can deliver digital imaging as part of the communication service

 

London, 30 July 2020: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, today announces that its flagship imaging-based communication platform, Bleepa, has been awarded a place on the NHSx National Clinical Communication Tool Framework ("the NCCT Framework"). Bleepa is a clinical communications platform that combines access to review quality medical imaging alongside instant messaging and video calling in one CE marked, zero footprint, medical device.

 

The NCCT Framework provides a vehicle for NHS Trusts to buy Bleepa by drawing down from a £3 million centralised fund over a two year period. It gives Bleepa national coverage and provides an independent validation of the quality and suitability of Bleepa for frontline delivery, a stamp of approval that the Company can use to also drive sales in other markets.

 

The Directors believe that as the only CE marked medical device relating to medical imaging on the NCCT Framework, Bleepa is the only supplier able to deliver digital patient imaging for diagnostic purposes alongside clinical messaging. The Directors believe that Bleepa's simple messaging exchange will offer considerable benefit to clinicians and Trusts, enabling the NHS to purge the pager and replace it with a truly transformative solution that brings medical imaging into routine communication.

 

 

Dr Tom Oakley, CEO of Feedback, commented:

 

"Bleepa has set a new standard for medical communication tools. I am delighted Bleepa has been awarded a place on the NHSx Clinical Communication Tool framework which positions Bleepa in the vanguard of medical imaging communications and provides a vehicle for potential reimbursement whilst simultaneously making Bleepa available to the whole of the NHS."

 

 

# # #

 

 

Below is the full announcement made today by NHSx:

 

Clinical Communications Procurement Framework

The Procurement Framework aims to support NHS organisations with dedicated clinical facing communication and tasks management tools, to accelerate the adoption of proven technologies and to phase out pagers by the end of 2021.

 

The framework has been designed to provide a compliant and convenient route to market for all NHS organisations.

 

It allows clinicians to access a wide range of communication tools all under one procurement framework agreement. Participating authorities have the freedom and flexibility to make a direct award or undertake a mini-competition to meet the bespoke requirement of each customer.

 

The suppliers have been assessed to ensure that they meet all legislative requirements; therefore no formal tendering is required, saving valuable time and money in the procurement process. The framework contains large national companies but also a healthy number of regional SMEs, and all can showcase their products via the framework, helping buyers to make informed local decisions.

 

Framework date and duration

 

3 August 2020 to 3 August 2022. Possible further extension for 12 months.

 

Further information is available on the NHSx website at https://www.nhsx.nhs.uk/key-tools-and-info/clinical-communications-procurement-framework/

 

 

-Ends-

 

 

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO

+44 (0)1954 718072

IR@fbk.com

 

 

Allenby Capital Limited (Nominated Adviser)

David Worlidge / Asha Chotai

+44 (0)20 3328 5656

 

 

Peterhouse Capital Limited (Joint Broker)

Lucy Williams / Duncan Vasey

+44 (0)20 7469 0936

 

 

Stanford Capital Partners Limited (Joint Broker)

Patrick Claridge / John Howes

+44 20 3815 8880

 

 

Instinctif Partners

Melanie Toyne-Sewell / Phillip Marriage

+44 (0)20 7457 2020

+44 7890 022 814

feedbackplc@instinctif.com

 

Notes to editors

 

About Bleepa

 

Bleepa provides instant and remote access to clinical grade medical images through a zero footprint application. The majority of patient cases require medical imaging which can be seamlessly shared to the entire clinical team through Bleepa. Cases can be discussed through its secure instant messaging and image annotation, allowing comments and treatment decisions to be communicated instantly between team members. Bleepa can be accessed from any internet connected device including phones, tablets, laptops and desktops; clinicians can use their own devices and therefore no additional hardware is required.

 

About Feedback plc - www.fbk.com

 

Feedback plc (AIM: FDBK) is a specialist medical imaging technology company providing innovative software and systems, through its fully owned trading subsidiary, Feedback Medical Limited. Its products advance the work of radiologists, clinicians and medical researchers by improving workflows and giving unique insights into diseases, particularly cancer.

 

Feedback has launched Bleepa, a new secure, encrypted medical communication app for clinicians accessible through smartphones, tablets and desktops that facilitates rapid clinical messaging and review of medical grade imaging for all members of a clinical team, directly from a hospital Picture Archiving and Communications System (PACS). For more information on Bleepa, see www.bleepa.com.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCKKKBQQBKDAON
Date   Source Headline
22nd Apr 20262:10 pmRNSGrant of Options and PDMR dealing
20th Apr 20267:00 amRNSNHS Progress and Business Update
17th Feb 202610:43 amRNSCorrection: Half-year Report
17th Feb 20267:00 amRNSHalf-year Report
2nd Feb 20267:00 amRNSNotice of Results & Retail Investor Presentation
5th Jan 20264:13 pmRNSHolding(s) in Company
23rd Dec 20253:44 pmRNSHolding(s) in Company
23rd Dec 20253:44 pmRNSHolding(s) in Company
23rd Dec 20253:33 pmRNSDirector/PDMR Shareholding
23rd Dec 20253:33 pmRNSDirector/PDMR Shareholding
18th Dec 20257:00 amRNSTrading Update
20th Oct 20257:00 amRNSDirectorate Change
13th Oct 20254:04 pmRNSResult of AGM
18th Sep 20251:07 pmRNSNotice of AGM
17th Sep 20257:00 amRNSFinal Results
8th Sep 20257:00 amRNSNotice of Results & Retail Investor Presentation
10th Jul 20257:00 amRNSGrant of Options and PDMR dealing
12th Jun 20257:00 amRNS-RNeighbourhood Health Service Simulation
7th May 202510:44 amRNSHolding(s) in Company
6th May 20251:01 pmRNSHolding(s) in Company
28th Apr 20257:00 amRNSTrading Update
25th Feb 20257:00 amRNSHalf-year Report
11th Feb 20257:00 amRNSNotice of Results & Investor Presentation
14th Jan 20257:00 amRNSSurrender and grant of options and PDMR dealings
18th Dec 20243:07 pmRNSHolding(s) in Company
18th Dec 20247:00 amRNSHalf Year Trading Update
9th Dec 202410:56 amRNSHolding(s) in Company
9th Dec 202410:48 amRNSHolding(s) in Company
4th Dec 20247:00 amRNSHolding(s) in Company
3rd Dec 202412:33 pmRNSHolding(s) in Company
3rd Dec 202412:18 pmRNSHolding(s) in Company
2nd Dec 202411:53 amRNSHolding(s) in Company
2nd Dec 202411:46 amRNSHolding(s) in Company
2nd Dec 20247:00 amRNSDirector/PDMR Shareholding
29th Nov 20243:36 pmRNSHolding(s) in Company
29th Nov 20243:33 pmRNSHolding(s) in Company
28th Nov 20242:35 pmRNSResult of AGM & Commercial Update
6th Nov 20247:00 amRNSResult of WRAP Retail Offer
4th Nov 20243:46 pmRNSSuccessful Fundraising upscaled to c. £5.57m
4th Nov 20247:02 amRNSWRAP Retail Offer for up to £1 million
4th Nov 20247:01 amRNSProposed Fundraise & Share Capital Reorganisation
4th Nov 20247:00 amRNSFinal Results
16th Oct 20247:00 amRNSElective Recovery Fund funding mechanism
19th Sep 20247:00 amRNSCollaboration Agreement
2nd Sep 20247:00 amRNSFurther funding to extend NHS Trust pathways
10th Jul 20247:00 amRNSVertex In Healthcare Collaboration
1st Jul 20247:00 amRNSCDC Contract Awarded by Queen Victoria Hospital
28th Jun 20247:00 amRNSChange of Name of Nominated Adviser and Broker
22nd May 20247:00 amRNSTrading Update
25th Mar 20247:00 amRNSNew tuberculosis partnership in India

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.